Sectors & Industries HealthcareDrug Manufacturers - General
Best General Drug Manufacturer Stocks to Buy Now (2025)
Top general drug manufacturer stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best general drug manufacturer stocks to buy now. Learn More.

Industry: Drug Manufacturers - Gene...

Zen Rating Price Value Growth Financials Momentum Sentiment Forecast Dividends Due Diligence

General Drug Manufacturers is Zen Rated A and is the 4th ranked industry out of 145 stock market industries

Ticker	Company	Exchange	Industry	Market Cap	Price	1d %	EBITDA	P/E	D/E	Country
GSK	GSK PLC	NYSE	Drug Manufacturers - General	$88.92B	$43.77	-0.02%	$7.47B	19.28x	3.04	United Kingdom
BIIB	BIOGEN INC	NASDAQ	Drug Manufacturers - General	$20.86B	$142.26	-0.97%	$2.61B	13.57x	0.61	United States
NVS	NOVARTIS AG	NYSE	Drug Manufacturers - General	$253.16B	$130.77	0.62%	$27.72B	18.92x	1.49	Switzerland
GRFS	GRIFOLS SA	NASDAQ	Drug Manufacturers - General	$6.70B	$9.75	1.67%	$1.71B	38.09x	2.18	United States
AMRN	AMARIN CORP PLC	NASDAQ	Drug Manufacturers - General	$415.10M	$20.07	0.50%	-$94.40M	-4.01x	0.44	Ireland
LLY	ELI LILLY & CO	NYSE	Drug Manufacturers - General	$775.51B	$819.38	-0.87%	$18.75B	53.38x	4.52	United States
AZN	ASTRAZENECA PLC	NASDAQ	Drug Manufacturers - General	$259.87B	$83.83	-1.18%	$18.51B	31.34x	1.51	United Kingdom
SNY	SANOFI	NASDAQ	Drug Manufacturers - General	$126.36B	$50.02	2.17%	$18.05B	11.52x	0.78	France
JNJ	JOHNSON & JOHNSON	NYSE	Drug Manufacturers - General	$462.69B	$192.12	0.50%	$35.65B	20.42x	1.46	United States
GILD	GILEAD SCIENCES INC	NASDAQ	Drug Manufacturers - General	$146.23B	$117.85	-0.38%	$10.97B	23.34x	1.84	United States
BMY	BRISTOL MYERS SQUIBB CO	NYSE	Drug Manufacturers - General	$88.32B	$43.39	-0.50%	$13.07B	17.43x	4.43	United States
ABBV	ABBVIE INC	NYSE	Drug Manufacturers - General	$400.78B	$226.87	0.29%	$13.80B	107.52x	-750.38	United States
AMGN	AMGEN INC	NASDAQ	Drug Manufacturers - General	$159.25B	$295.81	-0.51%	$15.89B	24.01x	10.83	United States
OGN	ORGANON & CO	NYSE	Drug Manufacturers - General	$2.44B	$9.38	-1.78%	$1.50B	3.46x	17.42	United States
PFE	PFIZER INC	NYSE	Drug Manufacturers - General	$137.76B	$24.23	-0.66%	$17.31B	12.82x	1.32	United States
SCLX	SCILEX HOLDING CO	NASDAQ	Drug Manufacturers - General	$92.55M	$13.31	-7.15%	-$68.46M	-1.24x	-1.34	United States
MRK	MERCK & CO INC	NYSE	Drug Manufacturers - General	$209.61B	$83.92	-0.23%	$25.03B	12.91x	1.40	United States
MIRA	MIRA PHARMACEUTICALS INC	NASDAQ	Drug Manufacturers - General	$34.32M	$1.80	36.36%	-$7.84M	-3.67x	0.52	United States
MDCX	MEDICUS PHARMA LTD	NASDAQ	Drug Manufacturers - General	$42.94M	$2.41	5.24%	-$16.73M	-1.80x	2.67	United States
NSRX	NASUS PHARMA LTD	NYSEMKT	Drug Manufacturers - General	N/A	$7.92	0.25%	-$1.50M	-36.00x	-1.22	Israel

General Drug Manufacturer Stocks FAQ

What are the best general drug manufacturer stocks to buy right now in Oct 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best general drug manufacturer stocks to buy right now are:

1. Gsk (NYSE:GSK)

Gsk (NYSE:GSK) is the #1 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Gsk (NYSE:GSK) is: Value: B, Growth: B, Momentum: C, Sentiment: B, Safety: B, Financials: B, and AI: C.

Gsk (NYSE:GSK) has a Due Diligence Score of 47, which is 8 points higher than the general drug manufacturer industry average of 39.

GSK passed 18 out of 38 due diligence checks and has strong fundamentals. Gsk has seen its stock return 11.63% over the past year, overperforming other general drug manufacturer stocks by 16 percentage points.

2. Biogen (NASDAQ:BIIB)

Biogen (NASDAQ:BIIB) is the #2 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Biogen (NASDAQ:BIIB) is: Value: A, Growth: C, Momentum: C, Sentiment: B, Safety: A, Financials: B, and AI: B.

Biogen (NASDAQ:BIIB) has a Due Diligence Score of 51, which is 12 points higher than the general drug manufacturer industry average of 39.

BIIB passed 15 out of 33 due diligence checks and has strong fundamentals. Biogen has seen its stock lose -24.73% over the past year, underperforming other general drug manufacturer stocks by -20 percentage points.

Biogen has an average 1 year price target of $175.43, an upside of 23.32% from Biogen's current stock price of $142.26.

Biogen stock has a consensus Buy recommendation according to Wall Street analysts. Of the 14 analysts covering Biogen, 28.57% have issued a Strong Buy rating, 28.57% have issued a Buy, 42.86% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Novartis Ag (NYSE:NVS)

Novartis Ag (NYSE:NVS) is the #3 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Novartis Ag (NYSE:NVS) is: Value: B, Growth: C, Momentum: B, Sentiment: C, Safety: B, Financials: B, and AI: B.

Novartis Ag (NYSE:NVS) has a Due Diligence Score of 39, which is equal to the general drug manufacturer industry average of 39.

NVS passed 14 out of 38 due diligence checks and has average fundamentals. Novartis Ag has seen its stock return 12.18% over the past year, overperforming other general drug manufacturer stocks by 17 percentage points.

Novartis Ag has an average 1 year price target of $118.00, a downside of -9.77% from Novartis Ag's current stock price of $130.77.

Novartis Ag stock has a consensus Strong Sell recommendation according to Wall Street analysts. Of the 1 analyst covering Novartis Ag, 0% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 100% have issued a Strong Sell.

What are the general drug manufacturer stocks with highest dividends?

Out of 12 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

1. Organon & Co (NYSE:OGN)

Organon & Co (NYSE:OGN) has an annual dividend yield of 6.4%, which is 4 percentage points higher than the general drug manufacturer industry average of 2.89%. Organon & Co's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Organon & Co's dividend has not shown consistent growth over the last 10 years.

Organon & Co's dividend payout ratio of 31.7% indicates that its high dividend yield is sustainable for the long-term.

2. Sanofi (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) has an annual dividend yield of 4.42%, which is 2 percentage points higher than the general drug manufacturer industry average of 2.89%. Sanofi's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Sanofi's dividend has shown consistent growth over the last 10 years.

Sanofi's dividend payout ratio of 51% indicates that its high dividend yield is sustainable for the long-term.

3. Merck & Co (NYSE:MRK)

Merck & Co (NYSE:MRK) has an annual dividend yield of 3.86%, which is 1 percentage points higher than the general drug manufacturer industry average of 2.89%. Merck & Co's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Merck & Co's dividend has shown consistent growth over the last 10 years.

Merck & Co's dividend payout ratio of 49.2% indicates that its dividend yield is sustainable for the long-term.

Why are general drug manufacturer stocks down?

General drug manufacturer stocks were down -0.39% in the last day, and down -2.26% over the last week. Eli Lilly & Co was the among the top losers in the drug manufacturers - general industry, dropping -0.87% yesterday.

Shares of GLP-1 drug manufacturers are trading lower following President Trump's comments that fat-loss drugs will be a lot lower in price.

What are the most undervalued general drug manufacturer stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued general drug manufacturer stocks right now are:

1. Organon & Co (NYSE:OGN)

Organon & Co (NYSE:OGN) is the most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Organon & Co has a valuation score of 71, which is 31 points higher than the general drug manufacturer industry average of 40. It passed 5 out of 7 valuation due diligence checks.

Organon & Co's stock has dropped -47.71% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -43 percentage points.

2. Merck & Co (NYSE:MRK)

Merck & Co (NYSE:MRK) is the second most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Merck & Co has a valuation score of 57, which is 17 points higher than the general drug manufacturer industry average of 40. It passed 4 out of 7 valuation due diligence checks.

Merck & Co's stock has dropped -24% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -19 percentage points.

3. Biogen (NASDAQ:BIIB)

Biogen (NASDAQ:BIIB) is the third most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Biogen has a valuation score of 86, which is 46 points higher than the general drug manufacturer industry average of 40. It passed 6 out of 7 valuation due diligence checks.

Biogen's stock has dropped -24.73% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -20 percentage points.

Are general drug manufacturer stocks a good buy now?

37.5% of general drug manufacturer stocks rated by analysts are a strong buy right now. On average, analysts expect general drug manufacturer stocks to rise by 9.3% over the next year.

15.79% of general drug manufacturer stocks have a Zen Rating of A (Strong Buy), 47.37% of general drug manufacturer stocks are rated B (Buy), 31.58% are rated C (Hold), 0% are rated D (Sell), and 5.26% are rated F (Strong Sell).

What is the average p/e ratio of the drug manufacturers - general industry?

The average P/E ratio of the drug manufacturers - general industry is 39.45x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.

General Drug Manufacturer Stocks FAQ

1. Gsk (NYSE:GSK)

2. Biogen (NASDAQ:BIIB)

3. Novartis Ag (NYSE:NVS)

1. Organon & Co (NYSE:OGN)

2. Sanofi (NASDAQ:SNY)

3. Merck & Co (NYSE:MRK)

1. Organon & Co (NYSE:OGN)

2. Merck & Co (NYSE:MRK)

3. Biogen (NASDAQ:BIIB)

Company

Stock Tools

Stock Ideas